Michael D. Wyzga - 16 Aug 2021 Form 4 Insider Report for YUMANITY THERAPEUTICS, INC. (KANT)

Role
Sr. VP & Chief Financial Officer
Signature
/s/ Marie Epstein, Attorney-in-Fact
Issuer symbol
KANT
Transactions as of
16 Aug 2021
Net transactions value
$0
Form type
4
Filing time
17 Aug 2021, 17:22:25 UTC
Next filing
03 Dec 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KA Stock Option (Right to Buy) Award $0 +65,000 $0.000000 65,000 16 Aug 2021 Common Stock 65,000 $9.17 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the option shall vest on August 16, 2022. The remaining 75% vest in equal monthly installments over the subsequent three years.

Remarks:

Sr. VP & Chief Financial Officer